NASDAQ:GHDX - Genomic Health Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $63.44 0.00 (0.00 %) (As of 11/8/2019) Add Compare Today's Range$63.44Now: $63.44▼$63.4450-Day Range$63.44MA: $64.79▼$69.7952-Week Range$50.77Now: $63.44▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/ABeta0.9 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GHDX Previous Symbol CUSIP37244C10 CIK1131324 Webhttp://www.genomichealth.com/ Phone650-556-9300Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96Price-To-Earnings Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/A Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Profitability EPS (Most Recent Fiscal Year)$1.05 Net Income$25.68 million Net Margins12.81% Return on Equity19.62% Return on Assets14.89%Miscellaneous Employees829 Outstanding Shares37,590,000Market Cap$2.38 billion Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive GHDX News and Ratings via Email Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter. Genomic Health (NASDAQ:GHDX) Frequently Asked Questions What is Genomic Health's stock symbol? Genomic Health trades on the NASDAQ under the ticker symbol "GHDX." How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) released its quarterly earnings data on Monday, November, 11th. The medical research company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.11. Genomic Health had a net margin of 12.81% and a return on equity of 19.62%. View Genomic Health's Earnings History. When is Genomic Health's next earnings date? Genomic Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Genomic Health. What price target have analysts set for GHDX? 8 brokers have issued twelve-month target prices for Genomic Health's stock. Their forecasts range from $55.00 to $72.00. On average, they anticipate Genomic Health's share price to reach $68.67 in the next year. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for Genomic Health. What is the consensus analysts' recommendation for Genomic Health? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health. What are Wall Street analysts saying about Genomic Health stock? Here are some recent quotes from research analysts about Genomic Health stock: 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019) 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019) Has Genomic Health been receiving favorable news coverage? News articles about GHDX stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genomic Health earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Genomic Health. Who are some of Genomic Health's key competitors? Some companies that are related to Genomic Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include NVIDIA (NVDA), Illumina (ILMN), Revance Therapeutics (RVNC), Horizon Therapeutics (HZNP), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), Baidu (BIDU), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH). Who are Genomic Health's key executives? Genomic Health's management team includes the folowing people: Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)Mr. G. Bradley Cole, Chief Financial Officer (Age 63)Dr. Frederic G. Pla, Chief Operating Officer (Age 60)Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56) Who are Genomic Health's major shareholders? Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (3.85%), Eagle Asset Management Inc. (1.22%), Carillon Tower Advisers Inc. (0.95%), Pictet Asset Management Ltd. (0.63%), Man Group plc (0.54%) and Russell Investments Group Ltd. (0.34%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health. Which institutional investors are selling Genomic Health stock? GHDX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, State Street Corp, Russell Investments Group Ltd., SG Americas Securities LLC, First Trust Advisors LP, AMI Asset Management Corp, Dupont Capital Management Corp and Voloridge Investment Management LLC. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber and Steven Shak. View Insider Buying and Selling for Genomic Health. Which institutional investors are buying Genomic Health stock? GHDX stock was acquired by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Eagle Asset Management Inc., Barclays PLC, State of New Jersey Common Pension Fund D, Squarepoint Ops LLC, GABELLI & Co INVESTMENT ADVISERS INC., Rhumbline Advisers and Gabelli Funds LLC. View Insider Buying and Selling for Genomic Health. What is Genomic Health's stock price today? One share of GHDX stock can currently be purchased for approximately $63.44. How big of a company is Genomic Health? Genomic Health has a market capitalization of $2.38 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.View Additional Information About Genomic Health. What is Genomic Health's official website? The official website for Genomic Health is http://www.genomichealth.com/. How can I contact Genomic Health? Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected] MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 326 (Vote Outperform)Underperform Votes: 378 (Vote Underperform)Total Votes: 704MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: Why is the LIBOR significant?